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Abstract: Asthma is a common chronic disease. Beclomethasone
dipropionate (BDP) and Fluticasone propionate (FP) are 2 inhaled
corticosteroids that frequently be used in treatment of patients with
asthma. In this study, the effectiveness of BDP and FP in management
of asthmatic children was investigated. In this trial, 50 children with
moderate persistent asthma were randomly selected to receive either
BDP 600g or FP 500g for 3 months. Pulmonary function tests were
measured in both groups at the beginning of study and monthly after
treatment. Daily and night symptoms and consistency of drugs were
also measured. There was significantly better FEV1 in patients receiv-
ing FP compared with the BDP group (P  0.01). There was also
statistically significant difference in patients receiving FP compared
with BDP group in increment of FVC, FEV1/FVC, FEF25–75 (P 
0.005). Night symptoms were significantly improved in the FP group
from the first month (P  0.001), while improvement of daily symp-
toms in this group compared with the BDP group was found from the
second month (P  0.001). Although symptoms and pulmonary func-
tion tests results were improved in both groups receiving either FP or
BDP, this study suggested that FP was more effective than BDP in
controlling moderate asthma in children.
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Asthma is a chronic inflammatory disorder of the airways.There is a remarkable increase in prevalence of asthma
worldwide, which makes it as one of the most common
chronic diseases, especially in childhood.1,2 The major char-
acteristics of asthma include variable degrees of airflow
obstruction, bronchial hyperresponsiveness and airway in-
flammation.3,4
Inhaled corticosteroids (ICS) reduce both asthma symp-
toms and marker of asthma inflammation.5 They are consid-
ered as the most potent and consistently effective long-term
controller medications for asthma.6,7 Fluticasone propionate
(FP) and beclomethasone dipropionate (BDP) are 2 com-
monly ICS for the treatment of asthma.
There were several studies to compare the effects of
these drugs in controlling asthma in different doses. This
study was performed to compare the efficacy and acceptabil-
ity of FP and BDP in nearly equal doses, in the treatment of
asthmatic children with moderate persistent asthma.
PATIENTS AND METHODS
Fifty patients with diagnosis of moderate persistent
asthma were enrolled in this study. The patients aged between
6 and 17 years and referred to the Allergy Clinic of Valie Asr
Hospital (Zanjan, Iran) with symptoms of moderate persistent
asthma within at least 6 months before enrollment. All these
patients had symptoms of cough and wheezing (at night and
after exercise) and a FEV1 of between 60–80% on the basis
of NAEPP guideline.3 Patients with other known causes of
wheezing, such as cystic fibrosis and heart disorders, were
excluded from this study. None of these patients had been
receiving any ICS before the study.
It was an open label study in which the patients were
randomly with unpredictable sequence, allocated into 2
groups. The first group received 250 g FP twice daily (2
puff BD) and the second group received 200 g BDP 3 times
daily (4 puff TDS) for 3 months. All children were instructed
to use ICS by mouthpiece spacer, provided by local company
(Asan Nafas, Tehran Fanavar Teb, Iran). Pulmonary function
tests (PFT) were done at the beginning of study and each
month till the end of this study. Occurrence of daily and night
symptoms and nonadherence of drug receiving were recorded
to dairy card and assessed monthly.
Both ICS were registered trade mark of Cipla Company
and prescribed open label; both of them had CFC propellant.
Pulmonary function tests were done by one person who did
not know any information about the kind of therapy. Spirom-
etry was performed with a Jaeger Master Scope Spirometer
(VIASYS Healthcare, Hochberg, Germany). The study pro-
tocol was approved by the Ethics Committee of Zanjan
University of Medical Science; all patients or their parents
gave written informed consent before enrollment. This study
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was also registered in the Iranian Registry of Control Trials
(IRCT: 138812042976N2).
The results are presented as mean  SD. The One-
Sample Kolmogorov-Smirnov Test procedure was performed
to check normal distribution of data by comparing the ob-
served cumulative distribution function for a variable with a
specified theoretical distribution. Comparisons of data be-
tween 2 groups were made using t test (for parametric data)
and Mann-Whitney U test (for nonparametric data), P 0.05
was considered as statistically significant. Repeated measure-
ment test were also used for comparing individual responses
to FP and BDP at 1, 2, and 3 months.
RESULTS
The patients aged 11.25  4.3 years and 12.8  4.4
years in FP and BDP groups, respectively. Baseline charac-
teristics were similar in both groups for PFT results, night
symptoms and asthma attacks at the beginning of the study
(Table 1).
Although there was significant improvement of FEV1
in both groups in 3 consecutive months after treatment, such
improvement in the FP group was significantly better than the
BDP group in first (87.3  11.1 vs. 79.8  7.8, P  0.008),
second (91.5  12.7 vs. 82.6  8.8, P  0.006), and third
(90.3  7.3 vs. 84.8  7.1, P  0.001) months. FVC and
FEF25–75 in the FP group were also significantly improved
compared with the BDP group in 3 consecutive months after
treatment (Table 2). Although there was not significant dif-
ference on FEV1/FVC in first month after treatment between
2 groups, significant improvement of FEV1/FVC in second
and third month of therapy with FP was found (P  0.001).
There were also significant improvement of night and daily
symptoms in the patients used FP, compared with the patients
used BDP (Table 2).
The mean frequency of night symptoms per month
before treatment was 6.3 in both groups. Although the
frequency of such symptoms were significantly decreased
after treatment with either FP or BDP group, there was
significantly improvement in the FP group (P  0.001).
Mean frequency of daily symptoms per week in the FP
group was also significantly improved compared with BDP
group (Table 2).
There was significant difference in drug nonadherence
in the first and second month, but there was no statistically
different in third month (Table 2). We analyzed the changes
between 2 groups during 3 consecutive months by repeated
measurement test. We found significant difference in FEV1
(P  0.001), FVC (P  0.003), FEV1/FVC (P  0.004), and
FEF25–75 (P  0.009). There was significant difference in
night symptoms (P  0.0001), daily symptoms (P  0.009),
and drug nonadherence (P 0.001). We did not find any side
effect or complication in both groups.
DISCUSSION
Inhaled corticosteroids are effective drugs for treatment
of asthma.6,7 This study showed that both FP and BDP can
improve the symptoms and PFT results. However, the degree
of improvement in daily and night symptoms and PFT results
among patients treated with FP was significantly better than
the BDP group. This could be because of differences in
pharmacokinetics and pharmacodynamics of FP and BDP.8
Although the results of our study was in agreement with
some previous studies toward benefit of FP than BDP,9–11 the
TABLE 1. Characteristics of Patients Who Received
Fluticason Propionate (FP) and Beclomethason Dipropionate
(BDP) at the Beginning of the Study
FP BDP P Value
Number of studied patients 25 25 —
Male/female 12/13 15/10 0.39
Age; year (mean  SD) 11.25  4.3 12.8  4.4 0.72
FEV1 (mean  SD) 71.68  5.76 69.48  4.69 0.155
FVC (mean  SD) 79.72  7.61 72.60  7.33 0.179
FEV1/FVC (mean  SD) 0.74  0.05 0.73  0.04 0.852
FEF25–75 (mean  SD) 49.6  6.09 47.32  6.34 0.201
Night symptoms* 6.32  1.22 6.28  1.24 0.880
Daily symptoms† 2.60  1.16 2.80  1.16 0.522
*Night problems per month. †Wheezing or cough per week need bronchodilator.
TABLE 2. Comparisons of Pulmonary Function Tests,
Symptoms and Drug Nonadherence in the FP and the BDP





Mean (SD) P Value
FEV1
First 87.36 (11.12) 79.84 (7.79) 0.008
Second 91.52 (12.67) 82.60 (8.76) 0.006
Third 90.32 (7.33) 84.84 (7.14) 0.001
FVC
First 82.52 (8.13) 77.80 (8.08) 0.045
Second 89.36 (9.53) 79.56 (7.64) 0.001
Third 90 (10.64) 82.86 (5.88) 0.004
FEV1/FVC
First 0.80 (0.046)% 0.79 (0.032)% 0.24
Second 0.85 (0.033)% 0.82 (0.017)% 0.001
Third 0.88 (0.029)% 0.83 (0.025)% 0.001
FEF25–75
First 59.20 (6.38) 54.72 (5.79) 0.012
Second 66.96 (4.81) 62.36 (4.81) 0.003
Third 73.6 (2.53) 70.0 (4.25) 0.001
Night symptoms
First 3.0 (1.08) 4.44 (0.92) 0.001
Second 2.12 (0.93) 3.28 (0.68) 0.001
Third 1.16 (0.85) 2.52 (0.51) 0.001
Daily symptoms
First 1.16 (0.89) 1.68 (1.07) 0.065
Second 0.40 (0.50) 1.28 (0.94) 0.001
Third 0.20 (0.41) 0.48 (0.51) 0.039
Drug nonadherence
First 0.72 (0.79) 1.48 (1.22) 0.023
Second 0.36 (0.63) 0.96 (0.84) 0.003
Third 0.4 (0.57) 0.64 (0.63) 0.156
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studies by Nong et al12 and Karakoc et al13 did not find any
significant difference in lung function improvement and symp-
tom scores in asthmatic children receiving either BDP or FP.
However, these studied might be limited by the fact that they
considered half dose of FP than BDP in their study.13 Other
studies showed CFC free product of BDP compared with FDP
(or beclomethasone/formeterole vs. fluticasone/salmeterole) ad-
ministration were equally effective for improving asthma control
in children with mild to moderate asthma at the same daily
dose.14,15 Molimard et al showed that efficacy of beclometha-
sone extrafine aerosol was significantly better than fluticasone
and budesonide.16 In our study, we used CFC-propelled BDP
and did not find better response by this product.
BDP was the first ICS, substituted for systemic corti-
costeroids in the treatment of chronic asthma.8 It is the
cheapest ICS currently available at both low and high doses
and may remain so even, when CFC-propelled products are
excluded,17 which might lead to good acceptance of BDP in
our patients. It should be noted that similar results were
achieved in drug administration in BDP and FP groups in
third month, despite greater daily doses of BDP than FP.
ICS are effective potent medication in asthma with fewer
side effects,7,18–20 but different studies showed increasing evi-
dence of adverse effects in patients treated with Fluticasone than
Beclomethasone.10,21–24 However, our patients did not have any
problem such as hoarseness, pharyngitis, or candidiasis of oro-
pharyngeal area during the study period. This may be because of
instruction of patients in using spacer and mouth rinsing after
drug prescribing and the short course of therapy.
It should be emphasized that conclusion from this study is
limited by the fact that we performed an open label study, and
we did not include a placebo control as it was unethical to keep
a group untreated. Indeed we compared CFC-BDP (with its
lower efficacy compared with FP at equivalent doses given TDS
(raising issues of adherence) with FP given at similar doses but
BD. However, BDP is a short acting ICS in comparison to FP,
and routinely prescribed more than 2 times a day, but FP could
be even prescribed once per day18; and thus, BDP was pre-
scribed more times than FP in our study. By the way, the patients
recruited and the methodology used should be taken into con-
sideration before generlizability of the findings.
In conclusion, this study showed that FP in a daily dose
of 500 g results in a significantly greater increase in PFT
results and improvement of symptoms than BDP at the dose
of 600 g in children with moderate asthma. Further studies
with different doses of these drugs and different types of ICS
are recommended to choose the best effective ICS with fewer
side effect and better acceptance for patients.
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